Last edition
News about "Phase 2 AZUR-1 trial"
GSK's Jemperli (dostarlimab) achieved durable complete responses in dMMR/MSI-H locally advanced rectal cancer, with potential to avoid chemotherapy, radiation, and surgery in some patients.
Phase 2 AZUR-1 Trial | 14/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members